Phase II study of neoadjuvant DCF therapy followed by adjvant S-1 monotherapy for pathological lymph node metastacis cases for locally advanced esophageal cancer. - Phase II study of neoadjuvant DCF followed by adjvant S-1 for pN+ forn locally advanced esophageal cancer.

The University of Tokyo0 个研究点目标入组 98 人开始时间: 2017年7月1日最近更新: 2024年1月22日

适应症

试验速览

暂无简介。

•1.Synchronous or metachronous (within 5 years) double cancers, except for intoramucosal tumor curatively resected by local therapy 2.With active systemic infection disease 3.With active hepatitis B or C 4.With HIV infection 5.With a history of interstitial pneumonia, pulmonary fibrosis or irradiation pneumonitis 6.Severe psychological illness. 7.With continuous systemic steroid or immune-suppressive drug therapy. 8.Poorly controlled diabetes mellitus or thyroid diseases. 9.Unstable angina within 3 weeks or with a history of acute myocardial infarction within 3months 10.With a history of hypersensitivity to docetaxel, cisplatin or polysorbate 80-containing formulations 11.Pregnant and/or nursing women or men who wish to have children in future 12.Judged to be unfit to participate in this study by investigator

发起方